News

April 28, 2025

Cellphire Therapeutics Welcomes Randall Stanicky to its Board of Directors

April 22, 2025

CRYPTICS Phase 2/3 Clinical Study stopped early for efficacy following pre-planned interim analysis by Independent Data Monitoring Committee (IDMC)

March 11, 2025

Cellphire Therapeutics CLPH-511 Fast Track Designation Granted!

FDA has granted CLPH-511 Fast Track Designation for the treatment of acute hemorrhage as an alternative to conventional platelets when not available or in short supply!

February 18, 2025

Cellphire Therapeutics Reaches Interim Analysis Milestone of 150 Patients in Phase 2/3 CRYPTICS Clinical Study

Cellphire Therapeutics has completed enrollment of 150 subjects in its CRYPTICS clinical trial, triggering an interim analysis to evaluate the safety and efficacy of its investigational cryopreserved platelet product, CLPH-511, for uncontrolled bleeding in cardiopulmonary bypass surgery. This milestone brings the company closer to offering a platelet alternative with extended shelf life, potentially improving access to critical care.

August 5, 2024

Cellphire Therapeutics announces the addition of Dr. Damien Bates as Chief Medical Officer and transition of Allan Alexander, our current CMO to an advisory role.

We are excited to announce that Damien Bates, MD, PhD, FRACS, MBA joined the company as Chief Medical Officer.

June 10, 2024

Completion of Phase 2 clinical trial of Thrombosomes® (FPH) in Acute Thoracic Aortic Dissections (TTAD)

Cellphire Therapeutics acknowledges Rigshospitalet Copenhagen University Hospital for completing enrollment ahead of schedule in their study of Thrombosomes® (FPH) for Acute Aortic Dissections, marking a significant advancement in life-saving cellular therapeutics. Dr. Jakob Stensballe and Dr. Annette Ulrich led the Copenhagen team's exceptional effort, demonstrating a shared commitment to innovation and patient care, with optimism for the potential impact of FPH technology on improving patient outcomes.

June 3, 2024

Cellphire Therapeutics announces the addition of Dr. Ed Coles to its Program Management and Executive Leadership teams.

We are excited to welcome Dr Edward Coles to the Cellphire management team!

May 13, 2024

Cellphire Therapeutics Forms Strategic Partnership with Vitalant, Bolstering Support for Freeze-Dried Platelet Derived Hemostat and Cryopreserved Platelets

Cellphire is excited to announce a strategic partnership with Vitalant, one of the nation’s largest nonprofit blood and biotherapies healthcare organizations. The partnership includes an initial investment by Vitalant and support for Cellphire's product development and clinical manufacturing processes of its freeze-dried platelet derived hemostat (FPH) and Cryopreserved Platelets.